These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29945212)

  • 1. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
    Fox KAA; Eikelboom JW; Anand SS; Bhatt DL; Bosch J; Connolly SJ; Harrington RA; Steg PG; Yusuf S
    Eur Heart J; 2019 May; 40(18):1466-1471. PubMed ID: 29945212
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
    Kruger PC; Eikelboom JW; Yusuf S
    Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
    Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim JH; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S;
    N Engl J Med; 2017 Oct; 377(14):1319-1330. PubMed ID: 28844192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
    Ambler GK; Nordanstig J; Behrendt CA; Twine CP
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837
    [No Abstract]   [Full Text] [Related]  

  • 6. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding rivaroxaban to aspirin after CABG surgery.
    Lim GB
    Nat Rev Cardiol; 2019 Mar; 16(3):133. PubMed ID: 30692655
    [No Abstract]   [Full Text] [Related]  

  • 8. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Camm AJ
    Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
    [No Abstract]   [Full Text] [Related]  

  • 11. [The COMPASS study].
    Calabrò P; Gragnano F; Visconti LO
    G Ital Cardiol (Rome); 2018 Jan; 19(1):1-7. PubMed ID: 29451504
    [No Abstract]   [Full Text] [Related]  

  • 12. VOYAGER PAD contributes to medical therapy for peripheral artery disease.
    Farber A
    J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
    Hart RG; Sharma M; Mundl H; Kasner SE; Bangdiwala SI; Berkowitz SD; Swaminathan B; Lavados P; Wang Y; Wang Y; Davalos A; Shamalov N; Mikulik R; Cunha L; Lindgren A; Arauz A; Lang W; Czlonkowska A; Eckstein J; Gagliardi RJ; Amarenco P; Ameriso SF; Tatlisumak T; Veltkamp R; Hankey GJ; Toni D; Bereczki D; Uchiyama S; Ntaios G; Yoon BW; Brouns R; Endres M; Muir KW; Bornstein N; Ozturk S; O'Donnell MJ; De Vries Basson MM; Pare G; Pater C; Kirsch B; Sheridan P; Peters G; Weitz JI; Peacock WF; Shoamanesh A; Benavente OR; Joyner C; Themeles E; Connolly SJ;
    N Engl J Med; 2018 Jun; 378(23):2191-2201. PubMed ID: 29766772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for long term maintenance therapy of venous thromboembolism.
    Schellong S
    Vasa; 2013 Mar; 42(2):83-5. PubMed ID: 23485833
    [No Abstract]   [Full Text] [Related]  

  • 15. Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
    Welsh RC; Peterson ED; De Caterina R; Bode C; Gersh B; Eikelboom JW
    Am Heart J; 2019 Dec; 218():100-109. PubMed ID: 31715433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
    Patrono C
    Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
    [No Abstract]   [Full Text] [Related]  

  • 17. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
    Boden WE; Bhatt DL
    Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
    Gibler WB
    Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of rivaroxaban in the prevention of atherosclerotic events.
    Sanmartín M; Bellmunt S; Cosín-Sales J; García-Moll X; Riera-Mestre A; Almendro-Delia M; Hernández JL; Lozano F; Mazón P; Suarez Fernández C
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):771-780. PubMed ID: 31269825
    [No Abstract]   [Full Text] [Related]  

  • 20. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
    Weitz JI; Angiolillo DJ; Geisler T; Heitmeier S
    Thromb Haemost; 2020 Aug; 120(8):1147-1158. PubMed ID: 32594508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.